Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Partnering Interest In Infectious Disease Space Showing Promise Beyond HCV Hotspot

Executive Summary

Antiviral agents and vaccines for indications beyond the red-hot hepatitis C indication highlight the infectious diseases track at this year’s Therapeutic Area Partnerships conference.

You may also be interested in...



Biota To Become U.S. Company Through Merger With Nabi

Biota and Nabi have proposed a merger that will give the Australian company access to the U.S. biotech market and increase its cash on hand.

Agenus Extends Cash Runway In GSK Partnership Expansion

Agenus will have sufficient cash to last through 2013 as it focuses on furthering its immunotherapeutics, including HerpV for genital herpes and Prophage Series G vaccines for glioma.

FDA OK’s Insomnia Treatment Through Software Pre-Cert Program

Pear Therapeutics’ Somryst insomnia treatment tool has become the first FDA-cleared product that was reviewed through the agency’s Software Precertification Pilot Program.

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

PS054874

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel